Fatigue: Causes, Tests and Treatments

by | Jul 14, 2010


A green chalkboard with the message 'I LOVE YOU' written in white chalk.

Is fatigue slowing you down? Sixty million Americans are so fatigued that it interferes with their daily activities and prevents them from achieving their goals. Emotional causes account for 40-80% of the cases, while physical causes account for only 20-60%.

Causes of Fatigue

The first step to finding relief from your fatigue is to take inventory of the things that might be responsible for your fatigue. In my 25 years of practice, I have found the following four main categories to be the principal causes of fatigue.

Life Choices & Challenges:

1) Lack of Sleep

2) Stress

3) Poor Diet / Dehydration

4) Lack of Exercise

5) Caffeine, Alcohol, Drugs

Nutritional Deficiencies:

1) Iodine (required for Thyroid hormone production)

2) Chromium (regulates blood sugar and prevents low blood sugar and sugar cravings)

3) L-Tyrosine (the precursor of Dopamine, Norepinephrine and Epinephrine)

4) Vitamin C (required for the conversion of Dopamine into Norepinephrine)

5) CoEnzymeQ10 (requires B2, B3, B5, B6, B12 and Folate) (responsible for energy generation within most cells of the body)

Hormone Deficiencies:

1) Thyroid hormones (T3 and T4)

2) Adrenal hormones (Aldosterone, Cortisol)

3) Male & Female Hormones (Testosterone)

4) Energy Neurohormones/Neurotransmitters (Dopamine, Norepinephrine and Epinephrine)

5) Sleep Neurotransmitters (Serotonin, GABA)

Thyroid hormone deficiency causes you to feel tired when you wake up and when you are resting. The feeling of fatigue decreases as the morning goes on and you get active, but comes back as soon as you sit still. With adrenal Cortisol deficiency you feel profoundly tired in the afternoon and evening, wiped out after any stress and lightheaded every time you stand up from a seated position. With a Testosterone deficiency, you feel tired all of the time, with muscle and joint pains and fatigue that gets worse with any exertion, low sex drive and a no sense of well-being.

A deficienciy of Dopamine, Norepinephrine and Epinephrine cause you to feel fatigued, depressed, blah and apathetic. Low Serotonin and GABA will cause you to have significant difficulty falling asleep and staying asleep, with runaway thoughts that you cannot turn off so you can’t sleep. All of these cause fatigue. Determining which ones are deficient will enable you to take the nutritional building blocks to rebuild your levels and climb out of the fatigue doldrums, regain your energy and feel alive again.

Medical Conditions:

1) Anemia (Iron or B12 deficiency, blood loss, or anemia of chronic disease)

2) Diabetes

3) Cancer

4) Chronic Fatigue Syndrome

5) Emphysema

6) Heart disease

7) Kidney Failure

8 ) Liver Failure

9) Restless Leg Syndrome

10) Sleep Apnea

TESTS

  1. Complete Blood Count (CBC): Blood test for Anemia (most commonly Iron or B12 deficiency)
  2. Thyroid Blood Test: TSH (Thyroid Stimulating Hormone), free T3 and free T4.
  3. Adrenal Cortisol: Saliva hormone test collected 4 times during the day between 7AM and 10PM.
  4. Neurotransmitters (Dopamine, Norepinephrine, Epinephrine, Serotonin, GABA): Urine test.
  5. CoQ10: Blood Test measures the principal nutritional marker for energy generation by the body.

Click here to take the Comprehensive Fatigue Assessment to score your most likely, non-medical, causes of fatigue.

TREATMENTS

Top 5 Anti-Fatigue Supplements

  1. Peak Advantage High-Potency Multi-Vitamin
  2. Replenish
  3. Succeed
  4. Isocort
  5. CoQ10 MAX

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

13 + 12 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });